Home > Market > Market Stats >  Advanced Enzyme Technologies

Advanced Enzyme Technologies

Sector: Biotechnology & Drugs
Powered by
276.85 +8.75 (3.26%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 268.1
Today’s High 278.0
52 Week Low 257.0
52 Week High 421.0

Key Metrics

  • Market Cap (In Cr) 3092.32
  • Beta 0.61
  • Div. Yield (%) 0.36
  • P/B 2.82
  • TTM P/E 29.88
  • Peg Ratio 2.49
  • Sector P/E 13.19
  • D/E -
  • Open Price 268.1
  • Prev Close 268.1
View All Metrics on Mint Genie

Analysis

Price Analysis
  • 1 Week
    -2.67%
  • 3 Months
    4.18%
  • 6 Month
    -8.35%
  • YTD
    -15.19%
  • 1 Year
    -28.69%
Risk Meter
  • 31% Low risk
  • 31% Moderate risk
  • 31% Balanced Risk
  • 31% High risk
  • 31% Extreme risk
Recos
2 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 0
  • Sell
  • 1
  • Hold
  • 0
  • Buy
  • 1
  • Strong Buy
  • 0

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2022
  • Total Revenue
  • 529.38
  • Selling/ General/ Admin Expenses Total
  • 172.56
  • Depreciation/ Amortization
  • 34.98
  • Other Operating Expenses Total
  • 5.81
  • Total Operating Expense
  • 362.9
  • Operating Income
  • 166.48
  • Net Income Before Taxes
  • 171.06
  • Net Income
  • 119.58
  • Diluted Normalized EPS
  • 10.62
  • Period
  • 2021
  • Total Revenue
  • 501.84
  • Selling/ General/ Admin Expenses Total
  • 130.91
  • Depreciation/ Amortization
  • 28.41
  • Other Operating Expenses Total
  • 4.85
  • Total Operating Expense
  • 294
  • Operating Income
  • 207.84
  • Net Income Before Taxes
  • 210.37
  • Net Income
  • 146.2
  • Diluted Normalized EPS
  • 12.77
  • Period
  • 2020
  • Total Revenue
  • 443.99
  • Selling/ General/ Admin Expenses Total
  • 125.78
  • Depreciation/ Amortization
  • 25.78
  • Other Operating Expenses Total
  • 4.39
  • Total Operating Expense
  • 267.11
  • Operating Income
  • 176.88
  • Net Income Before Taxes
  • 179.16
  • Net Income
  • 129.29
  • Diluted Normalized EPS
  • 11.57
  • Period
  • 2019
  • Total Revenue
  • 419.59
  • Selling/ General/ Admin Expenses Total
  • 133.1
  • Depreciation/ Amortization
  • 21.12
  • Total Operating Expense
  • 258.73
  • Operating Income
  • 160.86
  • Net Income Before Taxes
  • 161.96
  • Net Income
  • 111.06
  • Diluted Normalized EPS
  • 9.94
  • Period
  • 2018
  • Total Revenue
  • 395.7
  • Selling/ General/ Admin Expenses Total
  • 118.96
  • Depreciation/ Amortization
  • 18.3
  • Total Operating Expense
  • 250.02
  • Operating Income
  • 145.68
  • Net Income Before Taxes
  • 138.97
  • Net Income
  • 90.05
  • Diluted Normalized EPS
  • 8.08
  • Period
  • 2017
  • Total Revenue
  • 343.09
  • Selling/ General/ Admin Expenses Total
  • 85.88
  • Depreciation/ Amortization
  • 12.76
  • Total Operating Expense
  • 204.32
  • Operating Income
  • 138.77
  • Net Income Before Taxes
  • 137.05
  • Net Income
  • 91.55
  • Diluted Normalized EPS
  • 8.33
View detailed financials on Mint Genie

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day273.29
  • 10 Day284.16
  • 20 Day279.29
  • 50 Day277.17
  • 100 Day278.41
  • 300 Day296.03

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 06-Aug-22
  • Quarterly Results
  • 20-May-22
  • Audited Results & Final Dividend
  • 05-Feb-22
  • Quarterly Results
  • 02-Nov-21
  • Quarterly Results
  • 07-Aug-21
  • Quarterly Results
  • 29-May-21
  • Audited Results & Final Dividend
  • 12-Feb-21
  • Quarterly Results

Company Profile

ABOUT Advanced Enzyme Technologies

  • Industry Biotechnology & Drugs
  • ISIN INE837H01020
  • BSE Code 540025
  • NSE Code ADVENZYMES

Advanced Enzyme Technologies Limited is an enzyme company. The Company is focused on the research and development, manufacturing and marketing of approximately 400 products, which is developed from over 68 indigenous enzymes and probiotics. It provides solutions to various industries, such as human health care and nutrition, animal nutrition, baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, dairy processing, specialty applications, textile processing and others. It offers products and solutions for human nutrition, which include serratiopeptidase, fungal lactase, fungal lipase and papain; animal nutrition, which include DigeGrain X, DigeGrain XL and DigeGrain M; food processing, including dairy and cheese processing and yeast processing, and non-food processing, including textiles processing, leather and bio-fuels. Its oils and fats processing include oil extraction, oil refining fish oil processing, biodiesel and oleochemicals.

MANAGEMENT

  • Beni Rauka Chief Financial Officer
  • Dipak Roda Senior Vice President - Business Development, Marketing
  • Mukund Kabra Whole Time Director
  • Martina Doering Managing Director and Head Of Business Development, evoxx technologies GmbH, Germany
  • Harshad Doshi Chief Financial Officer and Chief Operating Officer of the US subsidiaries
  • Michael Puls Managing Director and Head Of Research and Development, evoxx technologies GmbH, Germany
  • Sanjay Basantani Company Secretary, Head-Legal

Company Summary

ADVANCED ENZYME TECHNOLOGIES SUMMARY

Advanced Enzyme Technologies is trading 3.26% upper at Rs 276.85 as compared to its last closing price. Advanced Enzyme Technologies has been trading in the price range of 278.0 & 268.1. Advanced Enzyme Technologies has given -15.19% in this year & -2.67% in the last 5 days.

 

Advanced Enzyme Technologies has TTM P/E ratio 29.88 as compared to the sector P/E of 13.19. There are 2 analysts who have initiated coverage on Advanced Enzyme Technologies. There are 0 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 1 analysts have given the stock a sell rating.

 

The company posted a net profit of 17.87 Crores in its last quarter.

 

Listed peers of Advanced Enzyme Technologies include Shilpa Medicare (-0.04%), Indoco Remedies (1.96%), Advanced Enzyme Technologies (3.26%) etc.

FAQs about Advanced Enzyme Technologies

Advanced Enzyme Technologies is trading at 276.85 as on 4 Oct, 2022 3:53:52 PM. This is 3.26% upper as compared to its previous closing price of 268.1
The market capitalization of Advanced Enzyme Technologies is 3092.32 Cr as on 4 Oct, 2022 3:53:52 PM.
The average broker rating on Advanced Enzyme Technologies is Hold. The breakup of analyst rating is given below -
  • 0 analysts have given a strong sell rating
  • 1 analysts have given a sell rating
  • 0 analysts have given a hold rating
  • 1 analysts have given a buy rating
  • 0 analysts have given a strong buy rating
The 52 wk high for Advanced Enzyme Technologies is 421.0 whereas the 52 wk low is 257.0
Advanced Enzyme Technologies can be analyzed on the following key metrics -
  • TTM P/E: 29.88
  • Sector P/E: 13.19
  • Dividend Yield: 0.36%
  • D/E ratio: -
Advanced Enzyme Technologies reported a net profit of 119.58 Cr in 2022.

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout